A second positive Phase III data readout in two months has propelled Intellia Therapeutics (Nasdaq: NTLA) shares up over 76% in the past six months, including a notable 29% increase this past week. This surge follows the successful meeting of three key secondary endpoints by the company’s lead pipeline candidate, lonvoguran ziclumeran (lonvo-z), in a pivotal study targeting hereditary angioedema (HAE).
In the Phase III HAELO trial, lonvo-z demonstrated an 87% reduction in mean monthly attacks compared to placebo, alongside a significant 62% of patients in the treatment arm being entirely attack-free during the six-month evaluation period. These results were presented at the European Academy of Allergy & Clinical Immunology Annual Congress and published in The New England Journal of Medicine. The robust data has enabled Intellia to advance its rolling Biologics License Application (BLA), with expectations for completion by year-end and potential FDA approval by mid-2027.
Intellia’s CEO, John Leonard, expressed satisfaction with the results, highlighting the drug’s potential to redefine treatment paradigms in HAE, a market perceived by some investors as saturated due to existing therapies. Analysts have noted that the latest data strengthens the case for lonvo-z’s regulatory approval as a one-time treatment, suggesting that the unique benefits of this therapy could attract both physician and payer interest, despite competition in the HAE market.
Get started today with Solo access →
